Journal of Pharmynexa Research & Reports

Aim and Scope

The Journal of Pharmynexa Research & Reports is an open-access, peer-reviewed international journal dedicated to advancing the frontiers of pharmaceutical sciences, drug discovery, clinical pharmacology, and therapeutic innovation[cite: 13]. The journal serves as a collaborative global platform for pharmacologists, pharmaceutical scientists, medicinal chemists, clinical researchers, and healthcare professionals to disseminate high-quality original research, critical reviews, case reports, and technological breakthroughs across all domains of pharmacy and therapeutic development[cite: 13].

Core Areas of Focus

1. Drug Discovery, Design & Medicinal Chemistry

• Molecular Design & Synthesis: Rational drug design, structure-activity relationship (SAR), computer-aided drug design (CADD), target identification, and lead optimization.

• Natural Products & Phytochemistry: Isolation, characterization, and pharmacological evaluation of bioactive natural compounds, ethnopharmacology, and phytomedicines.

• Chemical Biology & Biotherapeutics: Peptide synthesis, antibody-drug conjugates (ADCs), therapeutic proteins, and nucleic acid-based therapeutics.

2. Pharmaceutics & Advanced Drug Delivery Systems

• Formulation Science: Pre-formulation studies, solid-state characterization, oral delivery systems, parenteral preparations, and bioavailability enhancement.

• Nanomedicine & Targeted Delivery: Liposomes, polymeric nanoparticles, nano-emulsions, targeted therapeutic carriers, and smart stimuli-responsive delivery platforms.

• Biopharmaceutics & Pharmacokinetics: Absorption, distribution, metabolism, and excretion (ADME) profiling, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and bioequivalence studies.

3. Pharmacology & Toxicology

• Experimental & Molecular Pharmacology: Cellular signaling pathways, receptor pharmacology, enzyme inhibition, and mechanism-of-action studies.

• Preclinical & Safety Evaluation: In vitro and in vivo toxicological profiling, safety pharmacology, genotoxicity, immunotoxicity, and organ toxicity studies.

• Neuro-, Cardio- & Immuno-Pharmacology: Specialized therapeutics for central nervous system disorders, cardiovascular diseases, metabolic syndromes, and cancer immunotherapies.

4. Clinical Pharmacy & Translational Therapeutics

• Clinical Trials & Therapeutics: Phase I–IV clinical investigations, patient-tailored dose optimization, and biomarker-guided treatment evaluations.

• Pharmacovigilance & Patient Safety: Post-marketing surveillance, adverse drug reaction (ADR) monitoring, risk-benefit assessment, and therapeutic drug monitoring (TDM).

• Hospital & Community Pharmacy: Rational drug use, clinical pharmacy interventions, patient adherence, and evidence-based prescription practices.

5. Regulatory Affairs & Pharmaceutical Innovations

• Regulatory Science & Quality Assurance: Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), analytical method validation, and global regulatory submissions.

• Pharmaceutical Biotechnology & Bioprocessing: Fermentation technology, recombinant therapeutics, biosimilars, and continuous biomanufacturing.

• Digital Health & AI in Pharmacy: Machine learning applications in pharmaceutical development, artificial intelligence in target screening, and digital therapeutics.

Types of Articles Accepted

• Original Research Articles[cite: 13]

• Comprehensive & Systematic Reviews[cite: 13]

• Clinical Case Reports & Series[cite: 13]

• Short Communications & Rapid Reports[cite: 13]

• Mini-Reviews & Perspective Articles[cite: 13]

• Editorials & Letters to the Editor[cite: 13]

• Methodologies & Validation Protocols[cite: 13]

1. Accepted Manuscript Types

The journal accepts submissions across pharmaceutical, pharmacological, and clinical disciplines in the following formats:

• Original Research Articles: Full-length reports of novel experimental data, clinical studies, or drug formulations.

• Review & Mini-Review Articles: Comprehensive syntheses of existing literature on emerging pharmaceutical topics.

• Case Reports: Documented clinical cases, adverse drug reactions, or therapeutic outcomes.

• Short Communications / Brief Reports: Preliminary findings or methodological innovations.

• Editorials & Perspectives / Opinions: Expert commentaries on current industry trends, regulatory changes, or clinical controversies.

• Conference Presentations / Slides: PowerPoint presentations (PPT/PPTX) or video-based presentations.

2. Manuscript Structure & Preparation

Manuscripts should be submitted in editable formats (Microsoft Word .doc / .docx preferred).

1. Title Page:

   • Title: Concise, descriptive, and specific.

   • Author Details: Full names, institutional affiliations, city, country, and email addresses.

   • Corresponding Author: Marked with an asterisk (*), including full contact email and phone/address.

2. Abstract & Keywords:

   • Abstract: Typically 200–300 words summarizing the background, objective, methods, main findings, and conclusions.

   • Keywords: 4–6 relevant terms for indexing (e.g., Pharmacokinetics, Drug Delivery, Bioavailability).

3. Main Body (Standard IMRaD):

   • Introduction: Background context, problem statement, and study objectives.

   • Materials and Methods: Detailed experimental or clinical protocols enabling reproducibility.

   • Results: Clear data presentation supported by numbered figures and tables.

   • Discussion: Interpretation of results in context with existing scientific literature.

   • Conclusion: Summary of key implications and future directions.

4. Statements & Disclosures:

   • Conflict of Interest / Competing Interests: Explicit statement disclosing any financial or non-financial conflicts.

   • Funding / Financial Support: Grants and funding bodies listed.

   • Ethical Approval & Consent: Required for studies involving human subjects or animals (institutional review board approval details).

5. References:

   • Standard scientific numbering or author-date format (e.g., Vancouver or APA-aligned standard).

   • Include DOIs where available for all cited literature.

3. Peer Review & Editorial Workflow

• Plagiarism Screening: All manuscripts undergo software and manual plagiarism checks upon initial intake.

• Review Model: Single-blind peer review by field experts evaluating technical rigor, novelty, and clinical/scientific relevance.

• Licensing: Accepted articles are published under an open-access Creative Commons (CC BY) license, allowing free distribution with proper citation.

• DOI Allocation: Published papers are assigned permanent Digital Object Identifiers (DOIs) registered via CrossRef.

4. Submission Methods & Contact

Manuscripts can be submitted via:

• Online Portal: Through the publisher's portal at sbresearchandpublisher.com/submission

• Email Submission: Directly via email attachment to the editorial office (contact@sbresearchandpublisher.com or the journal's dedicated editorial inbox).